commercialization agreement

MyHealthChecked's kit uses Yourgene Health's Clarigene SARS-CoV-2 PCR test and EKF Diagnostics' PrimeStore MTM sample collection device.

The test is designed to assess the risk of a person developing severe disease if they contract COVID-19 based on a combination of genetic and clinical factors.

The test, developed at George Mason, measures HER2 activation in a breast cancer biopsy to help determine if a patient will respond to treatment.

The test will identify more than 100 pathogens, as well as drug resistance in viruses and bacteria.

The partners will commercialize a line of oncology mutation panels on the Stilla Naica digital PCR system.

The CRISPR-based test uses Mammoth's DETECTR BOOST platform and will be compatible with both nasal swab and saliva samples.

BillionToOne's assay detects SARS-CoV-2 in samples from nasal, nasopharyngeal, and oropharyngeal swabs and has a testing capacity of 1 million tests per day.

The companies will form a joint venture for Todos' cancer tests with Care GB owning 67 percent and Todos owning 33 percent of the new venture.

IncellDx has been developing a test for cytokine storm-related cytokines, which it said are elevated in COVID-19 patients who experience long-term symptoms.

HTG will work directly with biopharma customers to build companion diagnostic development programs, with potential tests developed using either a Thermo Fisher Scientific or Illumina platform.